Riikka Järvinen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/566149/publications.pdf

Version: 2024-02-01

		1162889	940416	
18	269	8	16	
papers	citations	h-index	g-index	
19	19	19	395	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Long-term Efficacy of Maintenance Bacillus Calmette-Guérin versus Maintenance Mitomycin C Instillation Therapy in Frequently Recurrent TaT1 Tumours without Carcinoma In Situ: A Subgroup Analysis of the Prospective, Randomised FinnBladder I Study with a 20-Year Follow-up. European Urology. 2009, 56, 260-265.	0.9	102
2	Overexpression of Human Chorionic Gonadotropin β Genes 3, 5 and 8 in Tumor Tissue and Urinary Cells of Bladder Cancer Patients. Tumor Biology, 2007, 28, 52-56.	0.8	29
3	Long-term Outcome of Patients with Frequently Recurrent Non–muscle-invasive Bladder Carcinoma Treated with One Perioperative Plus Four Weekly Instillations of Mitomycin C Followed by Monthly Bacillus Calmette-Guérin (BCG) or Alternating BCG and Interferon-α2b Instillations: Prospective Randomised FinnBladder-4 Study, European Urology, 2015, 68, 611-617.	0.9	27
4	Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non–Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study. European Urology, 2016, 70, 341-347.	0.9	23
5	Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette–Guérin instillation therapy of patients with carcinoma in situ of the bladder: A subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up. Scandinavian Journal of Urology and Nephrology, 2012, 46, 411-417.	1.4	16
6	Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era. Scandinavian Journal of Urology, 2018, 52, 419-426.	0.6	16
7	Outcome of surgery for patients with renal cell carcinoma and tumour thrombus in the era of modern targeted therapy. Scandinavian Journal of Urology, 2016, 50, 380-386.	0.6	12
8	A retrospective study on tolerability and complications of bacillus Calmette-Guérin (BCG) instillations for non-muscle-invasive bladder cancer. Scandinavian Journal of Urology, 2019, 53, 116-122.	0.6	12
9	Symptoms and diagnostic delays in bladder cancer with high risk of recurrence: results from a prospective FinnBladder 9 trial. World Journal of Urology, 2020, 38, 1001-1007.	1,2	9
10	Awareness of Smoking as a Risk Factor in Bladder Cancer: Results from the Prospective FinnBladder 9 Trial. European Urology Focus, 2022, 8, 1246-1252.	1.6	6
11	Incidence of and mortality from Bacille Calmetteâ€Guérin (BCG) infections after BCG instillation therapy. BJU International, 2022, 129, 737-743.	1.3	5
12	Perioperative management of radical cystectomy in the Nordic countries. Scandinavian Journal of Urology, 2019, 53, 51-55.	0.6	4
13	Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma. Scandinavian Journal of Urology, 2020, 54, 413-419.	0.6	3
14	Repeated 5-aminolevulinic Acid Instillations During Follow-up in Non-muscle-invasive Bladder Cancer: A Randomized Study. In Vivo, 2021, 35, 1561-1568.	0.6	2
15	Reply from Authors re: Robert S. Svatek. Long-term Outcomes of the FinnBladder-4 Study. Eur Urol 2015;68:618–9. European Urology, 2015, 68, 619-620.	0.9	1
16	Evolving Clinical Picture of Renal Cell Carcinoma: A Population-Based Study from Helsinki. Urologia Internationalis, 2019, 102, 390-398.	0.6	1
17	Hand-assisted laparoscopic versus open partial nephrectomy in patients with T1 renal tumor: Comparative perioperative, functional and oncological outcome. Scandinavian Journal of Urology, 2015, 49, 446-452.	0.6	1
18	Male urethral reconstruction using vagina as a substitute in a 45X/46XY case. Scandinavian Journal of Urology, 2017, 51, 502-503.	0.6	0